<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83524">
  <stage>Registered</stage>
  <submitdate>20/01/2009</submitdate>
  <approvaldate>16/04/2009</approvaldate>
  <actrnumber>ACTRN12609000174280</actrnumber>
  <trial_identification>
    <studytitle>The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study</studytitle>
    <scientifictitle>A randomised controlled trial of the beta-blocker carvedilol versus placebo to reduce cardiovascular morbidity and mortality in high-risk patients receiving dialysis: the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study</scientifictitle>
    <utrn />
    <trialacronym>BLOCADE</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cardiovascular disease</healthcondition>
    <healthcondition>end-stage kidney disease
haemodialysis
peritoneal dialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention is the beta-blocking agent carvedilol taken orally, twice daily.  Participants who tolerate 6.25mg twice daily in the active Run-in phase and are randomised to carvedilol will undergo titration of carvedilol from 6.25mg twice daily to 25mg twice daily or the highest tolerated dose.</interventions>
    <comparator>The control will be an identical placebo.  Participants who tolerate carvedilol 6.25mg twice daily in the active Run-in phase and are randomised to placebo will undergo titration of placebo from 6.25mg twice daily to 25mg twice daily or the highest tolerated dose in an identical fashion to participants receiving active drug.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tolerability: 1. The proportion of patients that fail to tolerate carvedilol during the active run-in phase.</outcome>
      <timepoint>The active Run-in phase will last six weeks and occur before randomisation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability: 2. The proportion of patients that fail to tolerate carvedilol after randomization.</outcome>
      <timepoint>Participants will be maintained on study drug for 12 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability: 3. The incidence of major adverse effects.  The major adverse effects expected are symptomatic hypotension and symptomatic bradycardia.  Symptomatic events will be identified by treating staff, notified to study personnel and reported through the adverse event Case Report Form.</outcome>
      <timepoint>This outcome will be assessed in both the Run-in phase (6 weeks before randomisation) and for 12 months after randomisation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in B-type Natriuretic Peptide (BNP) level between baseline and after 12 months of therapy with study drug.  BNP assays will be performed by a central laboratory on stored serum at the end of the study.  Both BNP and T-terminal BNP will be measured.</outcome>
      <timepoint>BNP will be measured at R0, 6 months and 12 months visit.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life will be measured using the EQ5D instrument.</outcome>
      <timepoint>Quality of Life (EQ5D) will be measured at Baseline, 6 months and 12 months visit.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The person has end-stage kidney disease and is receiving either haemodialysis or peritoneal dialysis 2. At the time of signing the consent form, the person is: i) Age &gt;50 years, OR ii) Age &gt;18 years with diabetes, OR iii) Age &gt;18 years and has clinical features of cardiovascular disease (myocardial infarction or ischaemic heart disease, ischaemic stroke or peripheral arterial disease).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Scheduled for live donor transplant within six months. 2. Experienced a cardiovascular event in the previous 3 months. Cardiovascular events include: myocardial infarction, admission for unstable angina, coronary revascularisation procedure, peripheral arterial revascularisation procedure or stroke. 3. Definite contra-indication to beta-blockers, such as: i) second or third degree atrioventricular block unless treated with a permanent pacemaker ii) sick sinus syndrome unless treated with a permanent pacemaker iii) clinically significant reversible bronchospasm iv) previous intolerance to beta-blockers v) other contra-indication 4. Currently taking a beta-blocker, verapamil, diltiazem or moxonidine and the treating nephrologist does not wish to stop these medications in order to enter the trial. 5. Considered by the treating nephrologist to be clinically or haemodynamically unstable for the study. 6. Unstable target weight (defined by a change of &gt;2.0kg in target base weight over the preceding month). 7. Severe hepatic dysfunction (transaminases &gt;3x higher than the upper normal limit) on the most recent liver function tests (if performed within 3 months). 8. Already involved in a clinical trial where the intervention being trialled is likely to confound the outcome of this trial. 9. Considered by the treating physician to have a life expectancy of less than 12 months. 10. Inability to provide consent or follow study instructions due to psychological illness or condition. 12. Pregnant or planning to be pregnant during the trial period. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>People who satisfy inclusion and exclusion criteria and who tolerate carvedilol 6.25mg twice daily at the end of the Run-in phase will be randomised to carvedilol or placebo.
Randomisation will be conducted utilising an Interactive Voice Response System (IVRS) to allocate the patient to a trial arm using dynamically allocated methods (Flexetrials, National Health and Medical Research Council Clinical Trials Centre, University of Sydney). Stratification will occur for study site and dialysis modality. Patients will be randomised to one of two treatment groups in equal proportion.  Participants will be allocated to medication packs at the site and participants, investigators, and outcome assessors will not know whether the medication pack contains active drug or placebo.</concealment>
    <sequence>Participants will be randomised using a computer-generated sequence, with stratification by site and dialysis modality (haemodialysis or peritoneal dialysis).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate>16/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>26/02/2013</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Royal Park campus - Parkville</hospital>
    <hospital>Logan Hospital - Meadowbrook</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>4102</postcode>
    <postcode>3168</postcode>
    <postcode>3052</postcode>
    <postcode>2050</postcode>
    <postcode>3084</postcode>
    <postcode>5000</postcode>
    <postcode>2145</postcode>
    <postcode>2065 - Royal North Shore Hospital</postcode>
    <postcode>4131 - Meadowbrook</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Middlemore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Australasian Kidney Trials Network- University of Queensland</primarysponsorname>
    <primarysponsoraddress>The University of Queensland
School of Medicine
Building 33, Ground Level
Princess Alexandra Hospital
Ipswich Road
Woolloongabba Qld 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Jacquot Collaborative Research Initiative Grant</fundingname>
      <fundingaddress>Royal Australasian College of Physicians
145 Macquarie Street,
Sydney, NSW, 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Cardiovascular lipid (CVL) Grant</fundingname>
      <fundingaddress>CVL Research Grants (Pfizer Australia)
38-42 Wharf Road
West Ryde NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>New Zealand Health Research Council Feasibility Study Grant 10/163</fundingname>
      <fundingaddress>Level 3 - ProCare Building
110 Stanley Street - access via Grafton Mews
Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council Project Grant APP1006171</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The BLOCADE Feasibility Study aims to inform the final design of a randomised controlled trial with clinically important endpoints to determine whether therapy with the beta-blocker carvedilol will reduce the cardiovascular morbidity and mortality of patients receiving dialysis. The major aim of the Feasibility Study is thus to determine the tolerability of carvedilol in this population. 
Participants will be patients over the age of 50 years, or those over 18 years with either diabetes or cardiovascular disease. After a run-in phase, patients will be randomised to carvedilol, titrated to the maximum tolerated dose or 25mg twice daily, or placebo titrated in an identical fashion. Patients will be followed for 12 months to determine tolerability in terms of the proportion of participants not tolerating carvedilol in the Run-in Phase and post Randomisation, as well as the incidence of major adverse effects. Other data such as rates of dropping out or dropping in will specifically inform the final sample size calculation, and data regarding recruitment rates and the numbers of patients tolerating each specific dose of carvedilol will assist with logistics. The Feasibility Study will recruit 150 participants and follow them for 12 months, at which time they will have a final study visit, then undergo supervised down-titration then cessation of study drug. 
The protocol of the proposed Clinical End-point Study will be written based on data from the Feasibility Study.</summary>
    <trialwebsite>http://www.aktn.org.au/trials/recruiting.php</trialwebsite>
    <publication>The ÃŸ-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.
Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group.
Am J Kidney Dis. 2015 Dec 22. pii: S0272-6386(15)01394-3. doi: 10.1053/j.ajkd.2015.10.029. 
PMID: 26717861 </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Medical Research Ethics Committee, University of Queensland</ethicname>
      <ethicaddress>The University of Queensland
Brisbane St Lucia QLD 4072</ethicaddress>
      <ethicapprovaldate>3/09/2010</ethicapprovaldate>
      <hrec>2009000775</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Matthew Roberts</name>
      <address>Eastern Health Integrated Renal Service
Level 2 | 5 Arnold Street | Box Hill VIC 3128 
</address>
      <phone>+61 3 90952410</phone>
      <fax>+61 3 98996810</fax>
      <email>Matthew.Roberts@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Liza Vergara</name>
      <address>Australasian Kidney Trials Network
The University of Queensland School of Medicine
Building 33, Ground Level 
Princess Alexandra Hospital
Ipswich Road 
Woolloongabba Qld 4102</address>
      <phone>+61 7 3176 5394</phone>
      <fax>+61 7 3176 5663</fax>
      <email>l.vergara@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Liza Vergara, BLOCADE Clinical Research Associate</name>
      <address>Australasian Kidney Trials Network
The University of Queensland School of Medicine
Building 33, Ground Level 
Princess Alexandra Hospital
Ipswich Road 
Woolloongabba Qld 4102</address>
      <phone>+61 7 31765394</phone>
      <fax>+61 7 31765663</fax>
      <email>l.vergara@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Matthew Roberts</name>
      <address>Eastern Health Integrated Renal Service
Level 2 | 5 Arnold Street | Box Hill VIC 3128 
</address>
      <phone>+61 3 90952410</phone>
      <fax>+61 3 98996810</fax>
      <email>Matthew.Roberts@easternhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>